Skip to main content
Erschienen in: Herz 4/2014

01.06.2014 | CME Zertifizierte Fortbildung

Risikofaktorenmanagement bei koronarer Herzerkrankung

Was ist evidenzbasiert?

verfasst von: Dr. E.B. Winzer, G.C. Schuler

Erschienen in: Herz | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Durch eine gezielte Behandlung von Risikofaktoren kann bei Patienten mit koronarer Herzerkrankung (KHK) der weitere Krankheitsverlauf maßgeblich beeinflusst werden. Eine Reduktion von Krankenhauseinweisungen, eine Verbesserung der Lebensqualität und eine Verlängerung der Lebenserwartung durch sekundärprophylaktische Maßnahmen sind gut belegt. Neben einer optimalen medikamentösen Therapie ist hierfür eine oft drastische Veränderung des Lebensstils mit den Schwerpunkten einer konsequenten Nikotinabstinenz, einer gesunden Ernährung und regelmäßiger körperlicher Aktivität notwendig. Daten aus der Versorgungsforschung zeigen, dass diese Ziele nur unzulänglich erreicht werden. Die Umsetzung der bestehenden Behandlungsleitlinien sollte daher mit Nachdruck verfolgt werden. Forschungsbedarf besteht insbesondere hinsichtlich der prognostischen Bedeutung einer Betablockertherapie bei Patienten mit stabiler KHK und erhaltener linksventrikulärer Funktion, der prognostischen Bedeutung einer gezielten Gewichtsreduktion bei KHK-Patienten mit Übergewicht und Adipositas, der Effektivität psychosozialer Interventionen bei unterschiedlichen Patientengruppen und deren Implementierung in die Routineversorgung sowie hinsichtlich der Optimierung von strukturierten Rehabilitationsprogrammen und der Verbesserung der Patienten-Compliance.
Literatur
1.
Zurück zum Zitat Beck EB, Walther C, Körner A, Erbs S (2010) Cardiovascular risk reduction in childhood – evidence and strategies. Eur Cardiol 5:34–39 Beck EB, Walther C, Körner A, Erbs S (2010) Cardiovascular risk reduction in childhood – evidence and strategies. Eur Cardiol 5:34–39
2.
Zurück zum Zitat Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937–952PubMedCrossRef Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937–952PubMedCrossRef
3.
Zurück zum Zitat World Health Organization (WHO) (2008) The global burden of disease: 2004 update. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf?ua=1 World Health Organization (WHO) (2008) The global burden of disease: 2004 update. http://​www.​who.​int/​healthinfo/​global_​burden_​disease/​GBD_​report_​2004update_​full.​pdf?​ua=​1
4.
Zurück zum Zitat Perk J, De Backer G, Gohlke H et al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33:1635–1701PubMedCrossRef Perk J, De Backer G, Gohlke H et al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33:1635–1701PubMedCrossRef
5.
Zurück zum Zitat Gohlke H, Albus C, Bönner G et al (2007) Leitlinie Risikoadjustierte Prävention von Herz- und Kreislauferkrankungen. http://leitlinien.dgk.org/files/2007_Leitlinie_Risikoadjustierte_Praevention.pdf Gohlke H, Albus C, Bönner G et al (2007) Leitlinie Risikoadjustierte Prävention von Herz- und Kreislauferkrankungen. http://​leitlinien.​dgk.​org/​files/​2007_​Leitlinie_​Risikoadjustiert​e_​Praevention.​pdf
6.
Zurück zum Zitat Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2006) Nationale VersorgungsLeitlinie Chronische KHK – Langfassung. Version 1.X. 2006 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2006) Nationale VersorgungsLeitlinie Chronische KHK – Langfassung. Version 1.X. 2006
7.
Zurück zum Zitat Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2011) NationaleVersorgungleitlinie Chronische KHK – Langfassung, Modul Medikamentöse Therapie, 2. Aufl. Version 1.X, 2011 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2011) NationaleVersorgungleitlinie Chronische KHK – Langfassung, Modul Medikamentöse Therapie, 2. Aufl. Version 1.X, 2011
8.
Zurück zum Zitat Smith SC Jr, Benjamin EJ, Bonow RO et al (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124:2458–2473PubMedCrossRef Smith SC Jr, Benjamin EJ, Bonow RO et al (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124:2458–2473PubMedCrossRef
9.
Zurück zum Zitat Heitzer T, Meinertz T (2005) Prevention of coronary heart disease: smoking. Z Kardiol 94(Suppl 3):III/30–III/42PubMedCrossRef Heitzer T, Meinertz T (2005) Prevention of coronary heart disease: smoking. Z Kardiol 94(Suppl 3):III/30–III/42PubMedCrossRef
10.
Zurück zum Zitat He J, Vupputuri S, Allen K et al (1999) Passive smoking and the risk of coronary heart disease – a meta-analysis of epidemiologic studies. N Engl J Med 340:920–926PubMedCrossRef He J, Vupputuri S, Allen K et al (1999) Passive smoking and the risk of coronary heart disease – a meta-analysis of epidemiologic studies. N Engl J Med 340:920–926PubMedCrossRef
11.
Zurück zum Zitat Hasdai D, Garratt KN, Grill DE et al (1997) Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 336:755–761PubMedCrossRef Hasdai D, Garratt KN, Grill DE et al (1997) Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 336:755–761PubMedCrossRef
12.
Zurück zum Zitat Gellert C, Schöttker B, Müller H et al (2013) Impact of smoking and quitting on cardiovascular outcomes and risk advancement periods among older adults. Eur J Epidemiol 28:649–658PubMedCrossRef Gellert C, Schöttker B, Müller H et al (2013) Impact of smoking and quitting on cardiovascular outcomes and risk advancement periods among older adults. Eur J Epidemiol 28:649–658PubMedCrossRef
13.
Zurück zum Zitat Stead LF, Bergson G, Lancaster T (2008) Physician advice for smoking cessation. Cochrane Database Syst Rev 2:CD000165PubMed Stead LF, Bergson G, Lancaster T (2008) Physician advice for smoking cessation. Cochrane Database Syst Rev 2:CD000165PubMed
14.
Zurück zum Zitat Ludvig J, Miner B, Eisenberg MJ (2005) Smoking cessation in patients with coronary artery disease. Am Heart J 149:565–572PubMedCrossRef Ludvig J, Miner B, Eisenberg MJ (2005) Smoking cessation in patients with coronary artery disease. Am Heart J 149:565–572PubMedCrossRef
15.
Zurück zum Zitat Rigotti NA, Pipe AL, Benowitz NL et al (2010) Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 121:221–229PubMedCrossRef Rigotti NA, Pipe AL, Benowitz NL et al (2010) Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 121:221–229PubMedCrossRef
16.
Zurück zum Zitat Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278PubMedCrossRef Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278PubMedCrossRef
17.
Zurück zum Zitat Cannon CP, Steinberg BA, Murphy SA et al (2006) Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48:438–445PubMedCrossRef Cannon CP, Steinberg BA, Murphy SA et al (2006) Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48:438–445PubMedCrossRef
18.
Zurück zum Zitat Preiss D, Sattar N (2009) Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol (Oxf) 70:815–828 Preiss D, Sattar N (2009) Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol (Oxf) 70:815–828
19.
Zurück zum Zitat HPS2-THRIVE Collaborative Group (2013) HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34:1279–1291 HPS2-THRIVE Collaborative Group (2013) HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 34:1279–1291
20.
Zurück zum Zitat Schwartz GG, Olsson AG, Abt M et al (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089–2099PubMedCrossRef Schwartz GG, Olsson AG, Abt M et al (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089–2099PubMedCrossRef
21.
Zurück zum Zitat Lewington S, Clarke R, Qizilbash N et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913PubMedCrossRef Lewington S, Clarke R, Qizilbash N et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913PubMedCrossRef
22.
Zurück zum Zitat Bangalore S, Steg G, Deedwania P et al (2012) beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308(13):1340–1349PubMedCrossRef Bangalore S, Steg G, Deedwania P et al (2012) beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308(13):1340–1349PubMedCrossRef
23.
Zurück zum Zitat Bao B, Ozasa N, Morimoto T et al (2013) β-Blocker therapy and cardiovascular outcomes in patients who have undergone percutaneous coronary intervention after ST-elevation myocardial infarction. Cardiovasc Interv Ther 28(2):139–147PubMedCrossRef Bao B, Ozasa N, Morimoto T et al (2013) β-Blocker therapy and cardiovascular outcomes in patients who have undergone percutaneous coronary intervention after ST-elevation myocardial infarction. Cardiovasc Interv Ther 28(2):139–147PubMedCrossRef
24.
Zurück zum Zitat Ozasa N, Morimoto T, Bao B et al (2012) β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol 168:774–779PubMedCrossRef Ozasa N, Morimoto T, Bao B et al (2012) β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol 168:774–779PubMedCrossRef
25.
Zurück zum Zitat Dickinson HO, Mason JM, Nicolson DJ et al (2006) Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 24:215–233PubMedCrossRef Dickinson HO, Mason JM, Nicolson DJ et al (2006) Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 24:215–233PubMedCrossRef
26.
Zurück zum Zitat Messerli FH, Mancia G, Conti CR et al (2006) Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144:884–893PubMedCrossRef Messerli FH, Mancia G, Conti CR et al (2006) Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144:884–893PubMedCrossRef
27.
Zurück zum Zitat DECODE Study Group, the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405CrossRef DECODE Study Group, the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397–405CrossRef
28.
Zurück zum Zitat Schondorf T, Lubben G, Karagiannis E et al (2010) Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study. Diab Vasc Dis Res 7:145–150PubMedCrossRef Schondorf T, Lubben G, Karagiannis E et al (2010) Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study. Diab Vasc Dis Res 7:145–150PubMedCrossRef
29.
Zurück zum Zitat Ryden L, Standl E, Bartnik M et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88–136PubMedCrossRef Ryden L, Standl E, Bartnik M et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88–136PubMedCrossRef
30.
Zurück zum Zitat Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef
31.
Zurück zum Zitat Thomas DE, Elliott EJ, Naughton GA (2006) Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 3:CD002968PubMed Thomas DE, Elliott EJ, Naughton GA (2006) Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 3:CD002968PubMed
32.
Zurück zum Zitat Turnbull FM, Abraira C, Anderson RJ et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288–2298PubMedCrossRef Turnbull FM, Abraira C, Anderson RJ et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288–2298PubMedCrossRef
33.
Zurück zum Zitat Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328PubMedCrossRef Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328PubMedCrossRef
34.
Zurück zum Zitat Eilat-Adar S, Eldar M, Goldbourt U (2005) Association of intentional changes in body weight with coronary heart disease event rates in overweight subjects who have an additional coronary risk factor. Am J Epidemiol 161:352–358PubMedCrossRef Eilat-Adar S, Eldar M, Goldbourt U (2005) Association of intentional changes in body weight with coronary heart disease event rates in overweight subjects who have an additional coronary risk factor. Am J Epidemiol 161:352–358PubMedCrossRef
35.
Zurück zum Zitat Sierra-Johnson J, Romero-Corral A, Somers VK et al (2008) Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index. Eur J Cardiovasc Prev Rehabil 15:336–340PubMedCrossRef Sierra-Johnson J, Romero-Corral A, Somers VK et al (2008) Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index. Eur J Cardiovasc Prev Rehabil 15:336–340PubMedCrossRef
36.
Zurück zum Zitat Lavie CJ, De SA, Milani RV (2013) Is there an obesity, overweight, or lean paradox in coronary heart disease? Getting to the ‚fat‘ of the matter. Heart 99:596–598PubMedCrossRef Lavie CJ, De SA, Milani RV (2013) Is there an obesity, overweight, or lean paradox in coronary heart disease? Getting to the ‚fat‘ of the matter. Heart 99:596–598PubMedCrossRef
37.
Zurück zum Zitat Sattelmair J, Pertman J, Ding EL et al (2011) Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 124:789–795PubMedCentralPubMedCrossRef Sattelmair J, Pertman J, Ding EL et al (2011) Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 124:789–795PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Schuler G (2005) Physical activity. Z Kardiol 94(Suppl 3):III/11–III/14CrossRef Schuler G (2005) Physical activity. Z Kardiol 94(Suppl 3):III/11–III/14CrossRef
39.
Zurück zum Zitat Hambrecht R, Walther C, Mobius-Winkler S et al (2004) Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 109:1371–1378PubMedCrossRef Hambrecht R, Walther C, Mobius-Winkler S et al (2004) Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 109:1371–1378PubMedCrossRef
40.
Zurück zum Zitat Belardinelli R, Paolini I, Cianci G et al (2001) Exercise training intervention after coronary angioplasty: the ETICA trial. J Am Coll Cardiol 37:1891–1900PubMedCrossRef Belardinelli R, Paolini I, Cianci G et al (2001) Exercise training intervention after coronary angioplasty: the ETICA trial. J Am Coll Cardiol 37:1891–1900PubMedCrossRef
41.
Zurück zum Zitat Taylor RS, Brown A, Ebrahim S et al (2004) Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 116:682–692PubMedCrossRef Taylor RS, Brown A, Ebrahim S et al (2004) Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 116:682–692PubMedCrossRef
42.
Zurück zum Zitat Heran BS, Chen JM, Ebrahim S et al (2011) Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 7:CD001800PubMed Heran BS, Chen JM, Ebrahim S et al (2011) Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 7:CD001800PubMed
43.
Zurück zum Zitat European Heart Network (2011) Diet, Physical Activity and Cardiovascular Disease Prevention. http://www.ehnheart.org/publications/publications/publication/521-diet-physical-activity-and-cardiovascular-disease-prevention.html European Heart Network (2011) Diet, Physical Activity and Cardiovascular Disease Prevention. http://​www.​ehnheart.​org/​publications/​publications/​publication/​521-diet-physical-activity-and-cardiovascular-disease-prevention.​html
44.
Zurück zum Zitat Ladwig K-H, Lederbogen F, Albus C et al (2013) Positionspapier zur Bedeutung psychosozialer Faktoren in der Kardiologie – Update 2013. Kardiologe 7:7–27CrossRef Ladwig K-H, Lederbogen F, Albus C et al (2013) Positionspapier zur Bedeutung psychosozialer Faktoren in der Kardiologie – Update 2013. Kardiologe 7:7–27CrossRef
45.
Zurück zum Zitat Müller-Riemenschneider F, Damm K, Meinhard C et al (2009) Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease. GMS Health Technol Assess 5:Doc16PubMedCentralPubMed Müller-Riemenschneider F, Damm K, Meinhard C et al (2009) Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease. GMS Health Technol Assess 5:Doc16PubMedCentralPubMed
46.
Zurück zum Zitat Kotseva K, Wood D, De Backer G et al (2009) EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 16:121–137PubMedCrossRef Kotseva K, Wood D, De Backer G et al (2009) EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 16:121–137PubMedCrossRef
Metadaten
Titel
Risikofaktorenmanagement bei koronarer Herzerkrankung
Was ist evidenzbasiert?
verfasst von
Dr. E.B. Winzer
G.C. Schuler
Publikationsdatum
01.06.2014
Verlag
Urban & Vogel
Erschienen in
Herz / Ausgabe 4/2014
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-014-4108-z

Weitere Artikel der Ausgabe 4/2014

Herz 4/2014 Zur Ausgabe

Schwerpunkt

Synkope

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.